



December 13, 2022

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Financial and Consumer Services Commission (New Brunswick)
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities, Service Newfoundland and Labrador

Re: Prospectus supplement dated December 12, 2022

Aptose Biosciences Inc. is filing under cover of this letter a copy of a prospectus supplement dated December 12, 2022 (the "**Supplement**") to the base prospectus dated October 21, 2022 filed with the United States Securities and Exchange Commission as part of a registration statement on Form S-3 pursuant to the *United States Securities Act of 1933*, as amended, and the general rules and regulations promulgated thereunder. The Supplement is being filed on SEDAR for informational purposes only.

No securities commission or similar authority in Canada has in any way passed upon the merits of the securities qualified for sale in the United States under the attached Supplement and any representation to the contrary is an offence. The securities qualified for sale in the United States under the attached Supplement have not been and will not be qualified for sale under the securities laws of Canada or any province or territory of Canada and will not be offered for sale in Canada or to any resident of Canada and may not be offered or sold, directly or indirectly, in Canada, or to or for the account of any resident in Canada.

Yours truly,

APTOSE BIOSCIENCES INC.

(s) Fletcher Payne
Senior Vice President and Chief Financial Officer